OMC
TLSI icon

Old Mission Capital’s TriSalus Life Sciences TLSI Stock Holding History

Old Mission Capital’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18,695
Closed -$183K – 1776
2022
Q1 		$183K Buy
+18,695
New +$184K 0.01% 1070

Other funds holding TLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
IPCP
Iron Park Capital Partners New York $621K AUM 73.14% 1-Year Est. Return

Old Mission Capital's TLSI Position: Q2 2022 in Review

Old Mission Capital sold out of TriSalus Life Sciences (TLSI) in Q2 2022, closing a stake of 18,695 shares — an estimated $183K sold.

Old Mission Capital first reported a position in TLSI in Q1 2022 and held it in 1 quarter. The position peaked at $183K in Q1 2022. 72 funds tracked by Wall St. Rank hold TLSI as of Q2 2022.

  • Old Mission Capital reported no remaining TriSalus Life Sciences position as of Q2 2022 after selling out during the quarter.
  • Old Mission Capital sold 18,695 TriSalus Life Sciences shares in Q2 2022, an estimated $183K.
  • Old Mission Capital first reported a position in TriSalus Life Sciences in Q1 2022 and held it in 1 quarter.
  • Old Mission Capital's TriSalus Life Sciences position peaked at $183K in Q1 2022.
  • 72 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2022.

Based on Old Mission Capital's 13F filing for Q2 2022, filed 5 Aug 2022.